by April Breyer Menon | Mar 21, 2024
On March 13, 2024, Regeneron appealed the PTAB Board’s (“the Board”) recent Final Written Decisions (“FWDs”) that found claims of two Regeneron patents related to EYLEA® (aflibercept) unpatentable. In CAFC 24-1564 Regeneron appeals the Board’s FWD in IPRs brought by...
by April Breyer Menon | Mar 15, 2024
On March 13, 2024, Merck Sharp & Dohme, LLC (“Merck”) filed four additional IPRs challenging The Johns Hopkins University (“JHU”) patents covering methods of treatment using pembrolizumab, which Merck sells under the trade name Keytruda®. These follow four IPRs...
by April Breyer Menon | Mar 15, 2024
On March 11, 2024, the White House released President Biden’s FY 2025 Department of Health and Human Services (HHS) Budget in Brief, which outlines $130.7 billion in discretionary funding for HHS. Included in the budget proposal is a provision that would eliminate...
by April Breyer Menon | Mar 15, 2024
On March 5, 2024, the FDA approved Sandoz’s Jubbonti® and Wyost® (denosumab-bddz) as the first biosimilars of Amgen’s Prolia® and Xgeva® (denosumab). The launch date for these biosimilars has not been announced as Amgen and Sandoz continue their BPCIA litigation in...
by April Breyer Menon | Mar 13, 2024
Download PDF Download...